Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)

Leuk Lymphoma. 2021 Jun;62(6):1532-1535. doi: 10.1080/10428194.2021.1885658. Epub 2021 Mar 22.

Authors

Michael J Hochman¹, Megan Othus^{1

2}, Roland B Walter^{1

2}, Carole Shaw², Kelda Gardner¹, Mary-Elizabeth M Percival^{1

2}, Anna B Halpern^{1

2}, Paul C Hendrie¹, Brenda M Sandmaier^{1

2}, Elihu H Estey^{1

2}

Affiliations

¹ Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA.
² Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

PMID: 33752557
DOI: 10.1080/10428194.2021.1885658

No abstract available

Publication types

Letter

MeSH terms

Flow Cytometry
Hematopoietic Stem Cell Transplantation*
Humans
Leukemia, Myeloid, Acute* / drug therapy
Neoplasm, Residual
Prognosis